About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Inflammatory Markers and Cognitive Function in Major Depression

NCT01391221·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Louise Normandeau, Nursing
CONTACT
514-251-4000 [email protected]
Souad Lhalafi, Nursing
CONTACT
514-251-4000 [email protected]

Lead

Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal

With

Eli Lilly and Company

Age

20–50

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age 20-50 Primary diagnosis of major depression Ability to give informed consent

You may not be if

Neurologic disorders affecting cognition
Unstable or untreated medical disorders
Medical disorders associated with pain
Recent pregnancy or delivery
Psychiatric disorders other than MD which are the primary focus of treatment
Treatment with antidepressants in the past 4 weeks

The record

StatusUnknown

PhasePhase 4

Taking part20

StartedJul 2011

UpdatedJul 19, 2012

Conditions

Major Depression

Where2

Centre de Recherche Fernand Seguin
Montreal, Quebec, Canada
Hôpital Maisonneuve Rosemont
Montreal, Quebec, Canada

Clareo Health | Inflammatory Markers and Cognitive Function in Major Depression